An Expert’s Perspective on the Expanded Approval of Venetoclax

Published on

Topics include: Treatment

What new treatment opportunities will the recent approval for the expanded use of venetoclax (Venclexta) provide for people living with chronic lymphocytic leukemia (CLL)?  CLL expert Dr. Susan O’Brien, from UC Irvine Health,shares exciting findings from the Murano trial that propelled the approval, how the label and uses have changed, and the impact it will have on CLL patients. Dr. O’Brien also discusses what kind of response is seen, the ability to achieve MRD negative and average rate of progression on venetoclax. How will patients with 17P deletion be affected? Will the approval make a difference in insurance coverage? Watch now to find out the latest CLL treatment news.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

View more programs featuring and

Related Programs

Looking Ahead: What Treatments Are in Development for CLL?

From CLL Live in Niagara Falls, Canada, Dr. Thomas Kipps provides expert insight into the evolving CLL treatment landscape. Watch now for the most recent updates in clinical research and targeted therapies.

Published:

Innovative Treatment Strategies for CLL: How Can Patients Become MRD Negative?

Is MRD negative status the treatment goal for CLL? How can patients with unique conditions reach it? CLL expert Dr. Nicole Lamanna discusses different approaches to therapy with novel agents.

Published:

Genetic Testing: What Version of CLL Do I Have and How Do I Treat It?

What do doctors look for in genetic tests for CLL patients? How do the results affect the course of treatment? Find out now from CLL expert Dr. Jennifer Brown.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on June 25, 2018